Thomas H Gillingwater Selected Research

Neuromuscular Diseases (Neuromuscular Disease)

11/2020	Renal pathology in a mouse model of severe Spinal Muscular Atrophy is associated with downregulation of Glial Cell-Line Derived Neurotrophic Factor (GDNF).
1/2018	Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands.
10/2017	In Vivo Translatome Profiling in Spinal Muscular Atrophy Reveals a Role for SMN Protein in Ribosome Biology.
1/2016	Restoration of SMN in Schwann cells reverses myelination defects and improves neuromuscular function in spinal muscular atrophy.
1/2016	Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy.
1/2016	Commonality amid diversity: Multi-study proteomic identification of conserved disease mechanisms in spinal muscular atrophy.
11/2014	Label-free quantitative proteomic profiling identifies disruption of ubiquitin homeostasis as a key driver of Schwann cell defects in spinal muscular atrophy.
1/2013	Spinal muscular atrophy: going beyond the motor neuron.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas H Gillingwater Research Topics

Disease

32	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 01/2021 - 12/2008
10	Wallerian Degeneration 04/2012 - 09/2003
8	Neuromuscular Diseases (Neuromuscular Disease) 11/2020 - 01/2013
6	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2018 - 06/2006
6	Motor Neuron Disease (Primary Lateral Sclerosis) 01/2018 - 12/2009
4	Atrophy 11/2014 - 12/2004
3	Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis) 12/2011 - 01/2008
2	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2017
2	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 06/2006
2	Non-alcoholic Fatty Liver Disease 01/2021 - 01/2019
2	Nervous System Diseases (Neurological Disorders) 01/2017 - 10/2016
2	Disease Progression 11/2013 - 01/2013
2	Paralysis (Palsy) 12/2008 - 04/2008
1	COVID-19 11/2021
1	Insulin Resistance 01/2021
1	Neoplasms (Cancer) 01/2020
1	Cachexia 01/2020
1	Dyslipidemias (Dyslipidemia) 01/2019
1	Hypoxia (Hypoxemia) 02/2016
1	Neurodevelopmental Disorders 04/2015
1	Intellectual Disability (Idiocy) 05/2012
1	Fragile X Syndrome (Martin Bell Syndrome) 05/2012
1	Multiple Sclerosis 02/2012
1	Inflammation (Inflammations) 02/2012
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 02/2012
1	Huntington Disease (Huntington's Disease) 01/2012
1	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 01/2012
1	Gliosis 10/2010
1	neuronal 5 Ceroid lipofuscinosis 07/2009
1	Pituitary Neoplasms (Pituitary Adenoma) 01/2008
1	Dementia (Dementias) 06/2006
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 06/2006
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 06/2006
1	Schizophrenia (Dementia Praecox) 06/2006
1	Wounds and Injuries (Trauma) 02/2006
1	Retrograde Degeneration 04/2004
1	Brain Ischemia (Cerebral Ischemia) 01/2004

Drug/Important Bio-Agent (IBA)

30	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2004
5	UbiquitinIBA 10/2018 - 01/2008
3	Pharmaceutical PreparationsIBA 01/2021 - 02/2012
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 11/2013 - 01/2013
2	Cathepsin DIBA 12/2011 - 01/2008
2	Botulinum Toxins (Botulinum Toxin)IBA 12/2008 - 04/2008
1	Caspase 3 (Caspase-3)IBA 01/2022
1	SuspensionsIBA 11/2021
1	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 11/2020
1	N 30IBA 01/2020
1	Lamin Type A (Lamin A)IBA 11/2019
1	Triglycerides (Triacylglycerol)IBA 01/2019
1	EnzymesIBA 10/2018
1	GlucocorticoidsIBA 05/2018
1	Amino Acids FDA Link 05/2018
1	nusinersenIBA 01/2018
1	neurochondrinIBA 01/2018
1	Antisense OligonucleotidesIBA 01/2018
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2017
1	SynucleinsIBA 01/2017
1	pimonidazoleIBA 02/2016
1	Glutathione (Reduced Glutathione)IBA 04/2015
1	HydrolasesIBA 12/2014
1	CateninsIBA 04/2014
1	Histone Deacetylase InhibitorsIBA 06/2013
1	Actins (F Actin)IBA 01/2013
1	glucose-regulated proteinsIBA 01/2013
1	mortalinIBA 01/2013
1	ProteomeIBA 01/2013
1	CalreticulinIBA 01/2013
1	Fragile X Mental Retardation ProteinIBA 05/2012
1	Fingolimod Hydrochloride (FTY720)FDA Link 02/2012
1	Apolipoprotein E3IBA 06/2011
1	Apolipoprotein E4IBA 06/2011
1	Apolipoproteins E (ApoE)IBA 06/2011
1	Neuroprotective AgentsIBA 11/2010
1	Peptide Elongation Factors (Elongation Factor)IBA 12/2008
1	Messenger RNA (mRNA)IBA 01/2008
1	Peptide Hydrolases (Proteases)FDA Link 01/2008
1	Nicotinamide-Nucleotide AdenylyltransferaseIBA 01/2008
1	NAD (NADH)IBA 01/2008
1	Ubiquitin-Activating Enzymes (Ubiquitin-Activating Enzyme)IBA 01/2008
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2008
1	Valosin Containing ProteinIBA 01/2008
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 08/2007
1	Guanine Nucleotide Dissociation Inhibitors (GDIs)IBA 08/2007
1	Nicotinamide MononucleotideIBA 02/2006
1	glutamine-synthetase adenylyltransferaseIBA 02/2006

Therapy/Procedure

10	Therapeutics 01/2021 - 02/2006
5	Denervation 01/2020 - 12/2004
4	Axotomy 04/2012 - 09/2003
1	Precision Medicine 01/2021
1	Behavior Control 05/2018